CIK 0000784199
- Large accelerated filer
ARTIVION, INC.
Sign in to watch- Ticker
- AORT
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 592417093
- Phone
- +1 770-419-3355
- Business address
- 1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
- Former names
- CRYOLIFE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,529,843
- in 3 filings
Net −$2,529,843. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Davis John E Chief Commercial Officer | Sale | −496 | $18.87 | $9K | 128,177 |
| 2024-02-20 | Maney Rochelle L. VP, Quality | Sale | −407 | $18.87 | $8K | 29,123 |
| 2024-02-20 | Getz Matthew A VP, Human Resources | Sale | −1,329 | $18.87 | $25K | 29,058 |
| 2024-02-20 | Getz Matthew A VP, Human Resources | Sale | −366 | $18.87 | $7K | 28,692 |
| 2024-02-20 | Tyrs Florian VP, Global Operations | Sale | −249 | $18.87 | $5K | 16,253 |
| 2024-02-20 | Mackin James P President & CEO | Option exercise | +59,225 | $16.30 | $965K | 611,105 |
| 2024-02-20 | Mackin James P President & CEO | Sale | −59,225 | $18.85 | $1.1M | 551,880 |
| 2024-02-20 | Mackin James P President & CEO | Sale | −10,088 | $18.87 | $190K | 541,792 |
| 2024-02-20 | Mackin James P President & CEO | Sale | −2,756 | $18.87 | $52K | 539,036 |
| 2024-02-20 | Mackin James P President & CEO | Option exercise · Stock Option(Right to Buy) | −59,225 | 0 | ||
| 2024-01-02 | Holloway Jean F SVP, General Counsel | Option exercise 10b5-1 | +21,229 | $16.30 | $346K | 154,749 |
| 2024-01-02 | Holloway Jean F SVP, General Counsel | Sale 10b5-1 | −21,229 | $18.00 | $382K | 133,520 |
| 2024-01-02 | Holloway Jean F SVP, General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,229 | $16.30 | $346K | 0 |
| 2024-01-02 | Davis John E Senior VP, Global Sales | Option exercise 10b5-1 | +13,562 | $16.30 | $221K | 142,295 |
| 2024-01-02 | Davis John E Senior VP, Global Sales | Sale 10b5-1 | −13,562 | $18.00 | $244K | 128,733 |
| 2024-01-02 | Davis John E Senior VP, Global Sales | Option exercise · Stock Option (Right to Buy) 10b5-1 | −13,562 | $16.30 | $221K | 0 |
| 2023-12-15 | Horton Amy VP, Chief Accounting Officer | Option exercise 10b5-1 | +14,397 | $16.30 | $235K | 138,437 |
| 2023-12-15 | Horton Amy VP, Chief Accounting Officer | Sale 10b5-1 | −14,397 | $19.00 | $274K | 124,040 |
| 2023-12-15 | Horton Amy VP, Chief Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,397 | $16.30 | $235K | 0 |
| 2023-12-06 | Berry Lance A Executive VP, CFO | Grant or award | +42,064 | $17.83 | $750K | 42,064 |
Page 19 of 20 · 388 trades